{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:03:35Z","timestamp":1769270615916,"version":"3.49.0"},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"DOI":"10.12788\/cutis.0681","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T15:22:11Z","timestamp":1676042531000},"source":"Crossref","is-referenced-by-count":2,"title":["Epidermal Growth Factor Receptor Inhibitor\u2013Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?"],"prefix":"10.12788","volume":"111","author":[{"given":"William","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","container-title":["Cutis"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/CT111001018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T15:22:13Z","timestamp":1676042533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/dermatology\/article\/260428\/nonmelanoma-skin-cancer\/epidermal-growth-factor-receptor-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,9]]},"published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.12788\/cutis.0681","relation":{},"subject":[],"published":{"date-parts":[[2023,1,1]]}}}